

Building a diverse and inclusive, interdisciplinary Alzheimer's disease and related dementias clinical and research infrastructure



Presented at the 2021 ELAM® Leaders Forum

Nancy L. Sicotte, MD, FAAN

SPONSORS Shlomo Melmed, MD, Sarah Kilpatrick, MD, PhD

BACKGROUND

- Cedars Sinai health system serves a diverse, rapidly aging population
- Disparities in dementia care and research participation results in knowledge gaps^{1,2}
- Scalable program for the health system needed
- Goal to achieve National Institute of Aging designation for ADRC (P30)

A recent gift provided support for a new clinical and research dementia program

OBJECTIVES

- 1. Develop organizational structure to support multiple missions
- 2. Engage institutional partners
- Develop health system strategy to foster inclusion and diversity
- 4. Determine research priorities
- 5. Set milestones for P30 grant submission

METHODS

- * Recruit key leaders
- Engage critical internal stakeholders
- Obtain community demographics
- ♣ Initiate clinical dementia program
- ♣ Promote collaborative research

RESULTS

Jona Goldrich Center for Alzheimers and Memory Disorders

Clinical

Research

Memory and Aging Program


Multidiscipli nary Clinic

Clinical Trials Basic Science

Biobank

- Collaborations: Geriatrics/Neurology/Psychiatry/Neuropsychology/ED/Nursing/Palliative Care
- Research Cohort: Asian American Pacific Islander (AAPI), LGTBQ+
- Collaborative Research: Pilot funding initiative launched internally
- Satellite clinics: South Bay, San Fernando Valley
- AAPI CME conference August 2021

P30/ADRC Milestones



DISCUSSION

- Significant progress made
- Unique opportunity for Neurosciences and the institution
- Lessons learned
 - It takes a village
 - Communication is key
 - Leadership matters
 - Covid challenges

NEXT STEPS

- Establish partnerships with AAPI and LGTBO+ communities
- 2. Database/Biobank development
 - . Develop research cores and leadership
- 4. Develop metrics for tracking diversity and inclusion
- 5. Recruit Center Director

CRITICAL PARTNERS

- Zaldy Tan, MD and Sarah Kremen, MD
- Keith Black, MD
- Itai Danovitch, MD
- · Jeffrey Golden, MD
- · Jennifer Blaha, SVP
- LC2 WELAM

Refs:

- 1. Mayeda et al: doi:10.1016/j.jalz.2015.12.007
- 2. Tsoy et al: doi:10.1001/jamaneurol.2021.0399